Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ocular Therapeutix Inc before investing.

In this article, we go over a few key elements for understanding Ocular Therapeutix Inc’s stock price such as:

• Ocular Therapeutix Inc’s current stock price and volume
• Why Ocular Therapeutix Inc’s stock price changed recently
• Upgrades and downgrades for OCUL from analysts
• OCUL’s stock price momentum as measured by its relative strength

About Ocular Therapeutix Inc (OCUL)

Before we jump into Ocular Therapeutix Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Want to learn more about Ocular Therapeutix Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ocular Therapeutix Inc.

Ocular Therapeutix Inc’s Stock Price as of Market Close

As of June 14, 2024, 4:00 PM, CST, Ocular Therapeutix Inc’s stock price was $5.75.

Ocular Therapeutix Inc is up 14.09% from its previous closing price of $5.04.

During the last market session, Ocular Therapeutix Inc’s stock traded between $4.83 and $5.44. Currently, there are 132.02 million shares of Ocular Therapeutix Inc stock available for purchase.

Unfortunately, Ocular Therapeutix Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Ocular Therapeutix Inc Stock Price History

Ocular Therapeutix Inc’s (OCUL) price is currently up 0.88% so far this month.

During the month of June, Ocular Therapeutix Inc’s stock price has reached a high of $6.08 and a low of $4.79.

Over the last year, Ocular Therapeutix Inc has hit prices as high as $11.31 and as low as $2.00. Year to date, Ocular Therapeutix Inc’s stock is up 104.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ocular Therapeutix Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 13, 2024, there were 6 analysts who downgraded Ocular Therapeutix Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ocular Therapeutix Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ocular Therapeutix Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ocular Therapeutix Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ocular Therapeutix Inc (OCUL) by visiting AAII Stock Evaluator.

Relative Price Strength of Ocular Therapeutix Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 13, 2024, Ocular Therapeutix Inc has a weighted four-quarter relative price strength of -1.59%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how Ocular Therapeutix Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ocular Therapeutix Inc Stock Price: Bottom Line

As of June 14, 2024, Ocular Therapeutix Inc’s stock price is $5.75, which is up 14.09% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ocular Therapeutix Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.